Integra Lifesciences Bolsa (NASDAQ: IART)

Últimas noticias sobre Integra Lifesciences (NASDAQ:IART) Bolsa

Integra Lifesciences

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences Holdings Corp

News

IART

Integra LifeSciences Holdings Corporation Subsidiary On Dec. 19 Received FDA Warning Letter; Says Submitted Several Responses To 2024 Form 483s Issued To Each Of The Three Manufacturing Facilities And Is In Process Of Preparing A Written Response To Warning Letter

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Sell and raises the price target from $16 to $22.

Price Target

Analyst Ratings

Citigroup Maintains Sell on Integra Lifesciences, Raises Price Target to $22

On Monday, Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) reported third-quarter adjusted EPS of $0.41, down from $0.76 a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.39</a>.
The company reported sales of $380.83 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41708174/integra-lifesciences-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $375.78 million</a>.
Third-quarter revenues of $380.8 million decreased 0.4% on a reported basis and 8.6% on an organic basis compared to the prior year. Revenue decreased by 10.3% on an organic basis, excluding Boston.
Codman Specialty Surgical&nbsp;segment sales increased 1% to $270.8 million, representing an organic decline of 10.7%. Tissue Technologies revenues were $110.1 million, representing a reported decline of 3.6% and an organic decline of 3.7%.
CEO Transition: Integra also announced Mojdeh Poul as Integra&#8217;s next president and chief executive officer.
Ms. Poul succeeds Jan De Witte, who previously announced he will retire as president and chief executive officer. Ms. Poul will join Integra on January 6, 2025.
Guidance: Integra LifeSciences revises its 2024 revenue outlook to $1.609 billion—$1.619 billion, compared to prior guidance of $1.609 billion—$1.629 billion and the consensus of $1.612 billion.
The company expects 2024 adjusted EPS of $2.41-$2.49, compared to prior guidance of $2.41-$2.57 and the consensus of $2.45.
Integra forecasts fourth-quarter 2024 revenue of $441 million—$451 million and adjusted EPS of $0.81-$0.89, versus the consensus of $448.5 million and $0.87, respectively.
Fourth-quarter guidance reflects the integration of Acclarent, stepped-up revenue from progress clearing the third-quarter shipping holds, and improved production for Integra Skin, partially offset by additional quality holds.
Price Action: IART stock is up 24.30% at $23.97 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41719755/stonepeak-lands-atsg-in-3-1-billion-deal-offering-29-premium-details" target="_blank" rel="noreferrer noopener">Stonepeak Lands ATSG In $3.1 Billion Deal, Offering 29% Premium: Details</a></li>
</ul>

Earnings

Large Cap

Guidance

Health Care

Management

Movers

General

Why Is Integra LifeSciences Stock Soaring On Monday?

U.S. stocks were lower, with the Dow Jones index falling around 300 points on Monday.
Shares of Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results.
Integra Lifesciences reported quarterly earnings of 41 cents per share which beat the analyst consensus estimate of 39 cents per share. The company reported quarterly sales of $380.83 million which beat the analyst consensus estimate of $375.78 million.
Integra LifeSciences shares jumped 24.4% to $23.96 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares jumped 43% to $66.22 after the company entered a securities purchase agreement for a PIPE investment, expected to bring in gross proceeds of $200 million.</li>
<li>Air Transport Services Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) gained 26.4% to $22.01 after the company announced it will be acquired by Stonepeak for approximately $3.1 billion, with shareholders receiving $22.50 per share in cash.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) rose 24.2% to $7.14. Xiao-I entered into private placement &amp; securities purchase agreement to issue, sell convertible promissory note for $2.1 million.</li>
<li>Disc Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) gained 22.9% to $57.93 after the company announced the end of its Phase 2 Bitopertin In Erythropoietic Protoporphyria meeting with the FDA. The company is aligned with the FDA across all proposed study parameters and has a clear development path to registration.</li>
<li>Globalstar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NASDAQ">GSAT</a>) gained 21.8% to $1.6800.</li>
<li>Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) rose 16% to $5.64.</li>
<li>The Chemours Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) gained 14.6% to $20.42 after the company reported better-than-expected quarterly financial results.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) rose 13.5% to $7.61.</li>
<li>Evotec SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NYSE">EVO</a>) jumped 13.1% to $4.3850.</li>
<li>LexinFintech Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LX#NYSE">LX</a>) gained 12.8% to $3.6100.</li>
<li>Freshpet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) gained 10.9% to $148.32 after the company reported better-than-expected quarterly financial results and raised its full-year adjusted EBITDA outlook.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) rose 9.4% to $10.88.</li>
<li>Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) surged 8.1% to $48.73 after the company reported better-than-expected quarterly EPS and revenues.</li>
<li>Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) gained 8% to $42.75.</li>
<li>Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) rose 7.5% to $7.80.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 7.5% to $1.2250.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) gained 7.3% to $29.13 after it was announced that the company will join the S&amp;P MidCap 400 prior to the opening of trading on Wednesday, Nov. 6.</li>
<li>Bath &amp; Body Works, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NASDAQ">BBWI</a>) rose 7.2% to $30.99.</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) gained 5.6% to $ 38.29</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713625/this-roblox-analyst-turns-bullish-here-are-top-5-upgrades-for-monday">This Roblox Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday</a></li>
</ul>

Intraday Update

Markets

AIXI

ARRY

ATSG

BBWI

CHWY

FRPT

GSAT

IRON

NGNE

PSNY

PTON

YUMC

Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 127.9% to $3.1 during Monday's regular session. The company's market cap stands at $5.7 million. </li>
<li>Singular Genomics Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) stock moved upwards by 58.24% to $21.3. The company's market cap stands at $53.1 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares increased by 44.04% to $66.36. The market value of their outstanding shares is at $862.2 million. </li>
<li>Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) stock rose 24.27% to $23.96. The company's market cap stands at $1.8 billion. As per the press release, Q3 earnings came out today. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock rose 23.42% to $1.37. The market value of their outstanding shares is at $22.3 million. </li>
<li>Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) shares moved upwards by 22.19% to $57.59. The market value of their outstanding shares is at $1.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares decreased by 15.8% to $1.98 during Monday's regular session. The company's market cap stands at $10.7 million. </li>
<li>BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) stock declined by 15.6% to $7.12. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares declined by 15.57% to $12.1. The market value of their outstanding shares is at $497.2 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares decreased by 15.52% to $14.87. The market value of their outstanding shares is at $22.2 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock declined by 13.5% to $2.05. The company's market cap stands at $349.8 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock decreased by 13.3% to $5.35. The market value of their outstanding shares is at $110.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCRX

BSGM

CVKD

DERM

NUWE

OMIC

THRD

TVGN

XTLB

12 Health Care Stocks Moving In Monday's Intraday Session

WIIM

Integra LifeSciences shares are trading higher after the company reported better-than-expected Q3 financial results.

Integra LifeSciences Expects Q4 2024 Revenue of $441M-$451M Compared To Consensus $448.474M

For the fourth quarter 2024, the Company expects reported revenues in the range of $441 million to $451 million, representing reported growth of 11.1% to 13.6% and organic growth of 2.0% to 4.5%. Fourth quarter guidance reflects the integration of Acclarent, stepped up revenue from progress clearing the third-quarter shipping holds, improved production for Integra Skin, partially offset by additional quality holds. The Company expects adjusted EPS in a range of $0.81 to $0.89.

Integra LifeSciences Expects Q4 2024 Adjusted EPS Of $0.81-$0.89 Compared To Consensus Of $0.87

Integra LifeSciences Expects 2024 Adjusted EPS Of $2.41-$2.49 Compared To Prior Guidance Of  $2.41-$2.57 Vs $2.45 Est.

For the full year 2024, the Company is updating its revenue and adjusted EPS ranges of $1.609 billion to $1.619 billion and $2.41 to $2.49, respectively. The revenue range represents reported growth of 4.4% to 5.0% and
For the full year 2024, the Company is updating its revenue and adjusted EPS ranges of $1.609 billion to $1.619 billion and $2.41 to $2.49, respectively. The revenue range represents reported growth of 4.4% to 5.0% and organic growth of -1.7% to -1.0%.

Integra LifeSciences Expects 2024 Revenue of $1.609B-$1.619B Compared To Prior Guidance Of  $1.609B-$1.629B Vs $1.612B Est.

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.39 by 5.13 percent. This is a 46.05 percent decrease over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $380.83 million which beat the analyst consensus estimate of $375.78 million by 1.34 percent. This is a 0.41 percent decrease over sales of $382.42 million the same period last year.

Integra Lifesciences Q3 2024 Adj EPS $0.41 Beats $0.39 Estimate, Sales $380.83M Beat $375.78M Estimate

Integra LifeSciences Has Appointed Mojdeh Poul As The New President And Chief Executive Officer, Effective January 6, 2025, Succeeding Jan De Witte, Who Will Remain President And CEO Until January 6, 2025

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Hold and lowers the price target from $26 to $21.

Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $21

B of A Securities analyst Craig Bijou maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Underperform and lowers the price target from $26 to $18.

B of A Securities Maintains Underperform on Integra Lifesciences, Lowers Price Target to $18

BTIG analyst Ryan Zimmerman upgrades Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) from Sell to Neutral.

Upgrades

BTIG Upgrades Integra Lifesciences to Neutral

In the last three months, 10 analysts have published ratings on Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Integra Lifesciences and provided 12-month price targets. The average target is $25.1, accompanied by a high estimate of $35.00 and a low estimate of $16.00. Experiencing a 7.41% decline, the current average is now lower than the previous average price target of $27.11. 
<img src="https://www.benzinga.com/files/images/story/2024/1727805731_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Integra Lifesciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Sell</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$26.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$23.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Announces</td>
<td>Sell</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$32.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Integra Lifesciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Integra Lifesciences compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Integra Lifesciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Integra Lifesciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IART/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Integra Lifesciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Integra Lifesciences</h2>
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
<h3>Integra Lifesciences: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Integra Lifesciences's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 9.68%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Integra Lifesciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -2.97%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Integra Lifesciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.79%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.3%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.31, Integra Lifesciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 10 Analyst Insights On Integra Lifesciences

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Sell and lowers the price target from $20 to $16.

Citigroup Maintains Sell on Integra Lifesciences, Lowers Price Target to $16

BTIG analyst Ryan Zimmerman maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Sell and lowers the price target from $22 to $20.

BTIG Maintains Sell on Integra Lifesciences, Lowers Price Target to $20

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.88, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 6.86% decline, the current average is now lower than the previous average price target of $28.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1724342454_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Integra Lifesciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$26.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$23.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Announces</td>
<td>Sell</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$32.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Integra Lifesciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Integra Lifesciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Integra Lifesciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Integra Lifesciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IART/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Integra Lifesciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Integra Lifesciences</h2>
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
<h3>Unraveling the Financial Story of Integra Lifesciences</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Integra Lifesciences's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.68%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Integra Lifesciences's net margin is impressive, surpassing industry averages. With a net margin of -2.97%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Integra Lifesciences's ROE stands out, surpassing industry averages. With an impressive ROE of -0.79%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.3%, the company showcases effective utilization of assets.
Debt Management: Integra Lifesciences's debt-to-equity ratio is below the industry average. With a ratio of 1.31, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Integra Lifesciences Through The Eyes Of 8 Analysts

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Sell and lowers the price target from $23 to $20.

Citigroup Maintains Sell on Integra Lifesciences, Lowers Price Target to $20

Invesco Small Cap Value Fund Q3 2024 Commentary

Morgan Stanley assumed coverage of Integra LifeSciences (IART) with an Underweight rating with a price target of $20, down from $25. The firm maint...

Integra LifeSciences assumed with an Underweight at Morgan Stanley

Integra Lifesciences ( ($IART) ) just unveiled an announcement. Integra LifeSciences has adopted a change in control severance program effective Ja...

Integra Lifesciences Implements New Severance Program for Executives

Hartford MidCap Value Fund Q3 2024 Commentary

Citi says avoid these stocks in '25; SA Quant Ratings says not so fast

Wells Fargo analyst Vik Chopra maintained a Hold rating on Integra Lifesciences (IART – Research Report) yesterday. The company's shares closed yes...

Wells Fargo Sticks to Its Hold Rating for Integra Lifesciences (IART)

Analyst Craig Bijou of Bank of America Securities reiterated a Sell rating on Integra Lifesciences (IART – Research Report), with a price target of...

Sell Rating Issued for Integra Lifesciences Amidst FDA Warning and Leadership Changes

BTIG analyst Ryan Zimmerman maintained a Hold rating on Integra Lifesciences (IART – Research Report) today. The company's shares closed today at $...

Integra Lifesciences (IART) Gets a Hold from BTIG

BTIG analyst Ryan Zimmerman maintained a Hold rating on Integra Lifesciences (IART – Research Report) today. The company's shares closed last Frida...

BTIG Sticks to Its Hold Rating for Integra Lifesciences (IART)

Integra LifeSciences (IART) Holding announced the launch of its global medical education platform Integra Institute. This new digital resource is d...

Integra LifeSciences launches Integra Institute for HCPs

ASAN

BKLN

COHR

CQQQ

EWBC

EXPE

FBIN

GNTX

GTLS

ICUI

KBWB

KBWD

KBWY

LITE

MKSI

MTCH

NDAQ

NXPI

PCEF

PDBC

PLUG

PNQI

PRFZ

QQQJ

QQQM

RSPT

SCCO

SNDR

SOXQ

SPGP

SPHB

SPHD

SPHQ

SPLV

SPMO

TCBI

ULCC

WERN

XMMO

Press Releases

Integra LifeSciences Reports Second Quarter 2024 Financial Results

Integra LifeSciences Continues to Make Progress on Its ESG Strategy

Integra LifeSciences to Present at the 2024 Wells Fargo Healthcare Conference

Integra LifeSciences to Present at the 22nd Annual Morgan Stanley Healthcare Conference

Kaskela Law LLC Announces Shareholder Investigation of Integra LifeSciences Holdings Corp. (NASDAQ: IART) and Encourages Long-Term IART Shareholders to Contact the Firm

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Integra LifeSciences to Host Third Quarter 2024 Financial Results Conference Call on November 4, 2024

Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer

Integra LifeSciences Reports Third Quarter 2024 Financial Results

Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs)

Comments

Integra Lifesciences

Noticias

Últimas noticias sobre Integra Lifesciences (NASDAQ:IART) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL